Newsletter Subject

Introducing the Solving COVID newsletter

From

theweek.com

Email Address

newsletter@theweek.com

Sent On

Wed, Apr 29, 2020 05:32 PM

Email Preheader Text

A potential treatment shows promise, Oxford's vaccine seems effective in monkeys, and more 1. Gilead

A potential treatment shows promise, Oxford's vaccine seems effective in monkeys, and more 1. Gilead says clinical trials show coronavirus patients responding to antiviral drug 2. Oxford COVID-19 clinical trial aims for a viable [As a devoted reader of The Week, we wanted you to be the first to know about our new Solving COVID newsletter, a weekly roundup of the latest scientific advancements being made against the coronavirus pandemic. It tracks developments in testing, treating, and vaccinating. To receive the newsletter every week, sign up here.]( Solving COVID 1. [Gilead says clinical trials show coronavirus patients responding to antiviral drug]( A trial of the antiviral drug remdesivir has revealed promising results in treating COVID-19 patients, Gilead Sciences announced this week. The trial involved 397 patients with severe COVID-19 cases. At least 50 percent of the patients treated with a 5-day dosage of remdesivir improved, and more than half were discharged from the hospital within two weeks, Gilead says. There are caveats, of course. The trial wasn't evaluated against a control group of patients who didn't receive the drug. It's also unclear if the high survival and improvement rates may have been natural recoveries from less severe cases. Still, the news is considered encouraging, albeit far from a "home run," as former Food and Drug Administration Commissioner Scott Gottlieb said after seeing the results. He also reiterated that even if remdesivir is effective, it's a treatment, not a cure. [[CNBC]( mailto:?Subject=Gilead+says+clinical+trials+show+coronavirus+patients+responding+to+antiviral+drug%0A&body=Read the story here: 2. [Oxford COVID-19 clinical trial aims for a viable vaccine by September]( A team at Britain's Oxford University started human trials on a potential COVID-19 vaccine last week, with an aim "to have about a million doses by September once we have the results of our vaccine efficacy tests," says Adrian Hill, director of Oxford's Jenner Institute. The team is trialing an experimental recombinant viral vector vaccine called "ChAdOx1 nCoV-19," one of at least 70 vaccine candidates under development worldwide. Prof. Sarah Gilbert, who is leading the study, said she thinks the vaccine "has a very strong chance of working." Scientists at the National Institutes of Health's Rocky Mountain Laboratory in Montana tested the vaccine on six rhesus macaque monkeys after exposing them to heavy quantities of the coronavirus and found that more than four weeks later all six monkeys remained healthy. Dr. Vincent Munster, the researcher who conducted the test, notes the rhesus macaque is "pretty much the closest thing we have to humans," so the results are at least promising. [[BBC]( Telegraph]( mailto:?Subject=Oxford+COVID-19+clinical+trial+aims+for+a+viable+vaccine+by+September%0A&body=Read the story here: 3. [Researchers test female sex hormones as possible coronavirus treatment]( Because male coronavirus patients are getting severely ill and dying at higher rates from COVID-19 than women, some scientists think estrogen and other female sex hormones may hold the key for treatment. So, doctors on Long Island in New York and in the Los Angeles area are launching trials of two different hormones (estrogen and progesterone, respectively) to see if there's any truth to the hypothesis. Research has shown estrogen may have an effect on a protein the coronavirus uses on the surface of cells as an entry route. The hormone has been able to reduce the protein expression in rat kidneys, which certainly does not mean its success in humans is a given, but does signal effectiveness is at least possible. Of course, not everyone is convinced that hormones are a "silver bullet" against the virus, but the hormones in the trials are considered safe, so there seems little reason to nix the idea. [[The New York Times]( mailto:?Subject=Researchers+test+female+sex+hormones+as+possible+coronavirus+treatment%0A&body=Read the story here: 4. [DNA technology could block the coronavirus from infecting human cells]( Researchers at the University of Louisville believe they've developed a technology that could block the coronavirus from infecting human cells. It's based on a piece of synthetic DNA (also known as an aptamer) that targets and binds with a human protein called nucleolin. Early research and experiments indicate the aptamer may be effective at preventing the coronavirus from "hijacking" nucleolin to replicate inside the body. The Louisville team has applied the same aptamer in a variety of ways, and it has reportedly emerged as a potential therapeutic drug for multiple types of cancer. The university is trying to develop the potential treatment as quickly as possible, including sending an application to the Food and Drug Administration for approval to begin treating patients suffering severe cases of COVID-19. [[University of Louisville]( mailto:?Subject=DNA+technology+could+block+the+coronavirus+from+infecting+human+cells%0A&body=Read the story here: 5. [Common heartburn medicine being tested on COVID-19 patients]( A generic heartburn medicine called famotidine is being tested on COVID-19 patients in New York City. But don't rush to the drugstore just yet. There is no evidence yet that famotidine is effective at treating COVID-19, but the hope is that it could prevent the coronavirus from replicating by essentially preoccupying it, similar to how protease inhibitors stop HIV. Dr. Kevin Tracey, the head of Northwell Health's Feinstein Institute for Medical Research, said he got the idea to test the heartburn medicine from a colleague who observed improvement among COVID-19 patients in China who were taking famotidine. The drug was also near the top of a computer model's ranking of existing drugs that might work against the coronavirus. If the drug proves effective, "it's generic, it's plentiful, and it's inexpensive," Tracey tells CNN. The trial started March 13 and the first results won't be released for at least a few weeks. [[CNN]( mailto:?Subject=Common+heartburn+medicine+being+tested+on+COVID-19+patients%0A&body=Read the story here: [Read more coronavirus stories banner]( MOST POPULAR [How Tara Reade's allegations could bring down Joe Biden]( Damon Linker [The perils of Hooverism]( Ryan Cooper [A new research project is attempting to see if dogs can detect the coronavirus by smell]( Tim O'Donnell [This visualization shows how droplets from a single cough can infect an entire airplane]( Tim O'Donnell [AMC says it will no longer show Universal Pictures films because of Trolls World Tour move]( Peter Weber [Mass workplace, rent strikes planned for May 1]( April 29, 2020 [Elon Musk, who predicted 'close to zero' new coronavirus cases by the end of April, demands we 'free America']( April 29, 2020 [A new research project is attempting to see if dogs can detect the coronavirus by smell]( April 29, 2020 [Chan Zuckerberg Initiative donates $13.6 million to coronavirus antibody testing in San Francisco]( April 29, 2020 [Is this email not displaying correctly? View it in your browser.]( [Unsubscribe from this list |]( [Update subscription preferences |]( [Privacy Policy]( © 2015 THE WEEK PUBLICATIONS, INC. ALL RIGHTS RESERVED. THE WEEK ® IS A REGISTERED TRADEMARK OWNED BY FELIX DENNIS. Get 4 issues of The Week for only $8 [TRY IT OUT]( [TRY IT OUT]( [Subscribe]( [Subscriber login]( [Give a gift]( [Classroom subscriptions]( [Newsletters]( [Privacy policy]( [Terms & conditions]( [The Week UK]( [Contact Us]( [Ad info]( [RSS](

Marketing emails from theweek.com

View More
Sent On

10/11/2024

Sent On

08/11/2024

Sent On

08/11/2024

Sent On

07/11/2024

Sent On

07/11/2024

Sent On

06/11/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.